Carlos Medical Appoints Jang Seok-ju as New Co-CEO

Jang Seok-ju, New Co-CEO of Carlos Medical

[Asia Economy Reporter Chunhee Lee] Calos Medical, a venture company developing therapeutic medical devices, recently held a board meeting and announced on the 13th that it appointed Jang Seok-joo as the new co-CEO. Jang joined Calos Medical as Chief Technology Officer (CTO) of the R&D headquarters in May.

CEO Jang graduated from Seoul National University with a degree in Electrical Engineering and completed graduate studies at the same university. He earned a master's degree in Biomedical Engineering and a Ph.D. in Systems Engineering from Case Western Reserve University in the United States, focusing on electrical stimulation technology for muscle function recovery in patients with lower limb paralysis. After completing his doctoral program, he worked as a researcher at the U.S. Veterans Affairs (VA) hospital.

Since 2009, Jang served as a director at Jungwoo Medical and CEO of its subsidiary CorazonX. From 2013, he was an executive director at Medtronic Korea, overseeing multinational teams at Medtronic Innovation Centers in Korea, Brazil, and Turkey, gaining extensive R&D experience. Later, he served as head of the Interojo Technology Research Institute and executive director, developing a renal nerve ablation system using laparoscopy. He also co-founded the startup DeepCure, serving as its first CEO and CTO, demonstrating both management and R&D capabilities.

Kim Cheol-jun, CEO of Calos Medical, said, “The newly appointed CEO Jang Seok-joo is not only a scientist but also possesses excellent managerial skills, which will greatly contribute to Calos Medical’s transformation into a company of a new dimension.” He added, “As Calos Medical declared its second founding this year, we hope that all employees will unite as one team under CEO Jang Seok-joo to maximize their capabilities in achieving the company’s goals and vision.”

CEO Jang stated, “We will commercialize the DENEX™ catheter and generator and complete the initial public offering (IPO) within two years.” He expressed his ambition, saying, “Through the advancement of DENEX products and joint R&D to expand indications beyond hypertension, we will broaden Calos Medical’s business portfolio.”

Calos Medical started in 2012 as the medical device research institute of Handok and was established in 2015 with an investment of 10 billion KRW from the Korea Investment Global Pharmaceutical Industry Development Fund, created by Handok and Korea Investment Partners. Since then, it has raised an additional 18 billion KRW in investments and is accelerating domestic and European clinical trials while developing DENEX products targeting the global market.